Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Teruaki Okuda"'
Autor:
Toshiaki Maruyama, Naosuke Kamei, Satoshi Ujigo, Teruaki Okuda, Taiki Morisako, Yuji Tsuchikawa, Hiroki Fukui, Takashi Hashimoto, Takeshi Hiramatsu, Takuro Shimbo, Kazuyoshi Nakanishi, Kiyotaka Yamada, Kjell Olmarker, Yoshinori Fujimoto, Nobuo Adachi, Toshio Nakamae
Publikováno v:
European Spine Journal. 30:2020-2032
Treatment of low back pain (LBP) associated with elderly degenerative lumbar scoliosis (DLS) remains controversial. We have developed percutaneous intervertebral-vacuum polymethylmethacrylate injection (PIPI) targeting to the intervertebral vacuum as
Autor:
Taisuke Katoh, Tomoya Sameshima, Masato Yoshikawa, Tomoya Yukawa, Hideto Hara, Takatoshi Yogo, Russell Naven, Makoto Miyamoto, Ikuo Miyahisa, Yoshihiko Hirozane, Teruaki Okuda
Publikováno v:
Chemical Research in Toxicology. 33:154-161
Despite the recent advances in the life sciences and the remarkable investment in drug discovery research, the success rate of small-molecule drug development remains low. Safety is the second most influential factor of drug attrition in clinical stu
Autor:
Etsuo Kotani, Kazuyoshi Aso, Yohei Kosugi, Mochizuki Michiyo, Takuto Kojima, Takahiko Yano, Maiko Tanaka, Teruaki Okuda, Yuu Sako, Hideyuki Nakagawa, Yuji Ishichi, Naoyuki Kanzaki, Katsumi Kobayashi
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:1556-1570
Compound 1 exhibits potent binding inhibition activity against a corticotropin-releasing factor 1 (CRF1) receptor (IC50=9.5nM) and in vitro antagonistic activity (IC50=88nM) but is rapidly metabolized by human hepatic microsomes (182μL/min/mg). Here
Publikováno v:
Xenobiotica. 44:1135-1144
1. Recently, the Food and Drug Administration (FDA) and European Medicines Agency have shown decision trees to determine whether a drug candidate is an inhibitor of P-glycoprotein (P-gp). However, there has been no clear information on whether P-gp i
Autor:
Yasushi Fujioka, Teruaki Okuda, Hideki Hirabayashi, Yohei Kosugi, Toshiya Moriwaki, Tomoko Igari
Publikováno v:
Xenobiotica. 44:336-344
1. This study optimized the reported approach for the prediction of drug-drug interactions (DDIs) using hepatocytes suspended in serum (HHSS) and provided a practical usage of HHSS in the early and late phases of drug discovery. 2. First, the IC50 wa
Autor:
Michiyo, Mochizuki, Takuto, Kojima, Katsumi, Kobayashi, Etsuo, Kotani, Yuji, Ishichi, Naoyuki, Kanzaki, Hideyuki, Nakagawa, Teruaki, Okuda, Yohei, Kosugi, Takahiko, Yano, Yuu, Sako, Maiko, Tanaka, Kazuyoshi, Aso
Publikováno v:
Bioorganicmedicinal chemistry. 25(5)
Compound 1 exhibits potent binding inhibition activity against a corticotropin-releasing factor 1 (CRF
Autor:
Teruaki Okuda, Takashi Hashimoto, Nobuhiro Tanaka, Toshio Nakamae, Toshikatsu Kanazawa, Kiyotaka Yamada, Kjell Olmarker, Haruhiko Takata, Yoshinori Fujimoto, Takuro Shimbo, Takeshi Hiramatsu
Publikováno v:
Spine. 41(10)
STUDY DESIGN Prospective cohort study. OBJECTIVE To compare the novel treatment procedure with nonoperative treatment for low back pain (LBP) in elderly patients with degenerative lumbar scoliosis (DLS). SUMMARY OF BACKGROUND DATA Treatment of LBP as
Autor:
Takashi Hashimoto, Toshio Nakamae, Teruaki Okuda, Takuro Shimbo, Kiyotaka Yamada, Mitsuo Ochi, Yoshinori Fujimoto, Nobuhiro Tanaka, Takeshi Hiramatsu, Toshikatsu Kanazawa, Kjell Olmarker, Haruhiko Takata
Publikováno v:
Spine. 41(10)
STUDY DESIGN Cross-sectional study. OBJECTIVE To examine whether bone marrow edema is associated with low back pain in elderly patients with degenerative lumbar scoliosis. SUMMARY OF BACKGROUND DATA The cause of low back pain in degenerative lumbar s
Autor:
Yohei Kosugi, Teruaki Okuda, Toshiya Moriwaki, Tomoko Igari, Yoko Hara, Yasushi Fujioka, Hideki Hirabayashi
Publikováno v:
Xenobiotica. 42:127-138
Herein, we aimed to evaluate the recently proposed risk assessment strategies of a cytochrome P450 (CYP) mediated drug-drug interaction (DDI) according to the European Medicines Evaluation Agency (EMEA) draft guideline, and discuss the differences be
Autor:
Nobuyuki Matsunaga, Akihiro Tasaka, Satoru Asahi, Mari Adachi, Takahito Hara, Toshimasa Tanaka, Teruaki Okuda, Akio Ojida, Takenori Hitaka, Shuichi Furuya, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
Publikováno v:
Bioorganic & Medicinal Chemistry. 19:6383-6399
A novel naphthylmethylimidazole derivative 1 and its related compounds were identified as 17,20-lyase inhibitors. Based on the structure–activity relationship around the naphthalene scaffold and the results of a docking study of 1a in the homology